Skip to main navigation Skip to search Skip to main content

ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17).

  • Yaewon Yang
  • , Eun Joo Kang
  • , Soohyeon Lee
  • , Yu Jung Kim
  • , Sun Min Lim
  • , Myung Ju Ahn
  • , Youngjoo Lee
  • , Tae Min Kim
  • , Ilhwan Kim
  • , Hee Kyung Ahn
  • , Soonil Lee
  • , So Yeon Oh
  • , Bae Woo Kyun
  • , Hyewon Ryu
  • , Kyong Hwa Park
  • , Ki Hyeong Lee

Research output: Contribution to journal › Article › peer-review

1   Link opens in a new tab Citation (Scopus)

Fingerprint

Dive into the research topics of 'ctDNA as a biomarker in phase II study of tepotinib in advanced solid cancers with MET exon 14 skipping mutation or amplification (KCSG AL19-17).'. Together they form a unique fingerprint.
Sort by

Biochemistry, Genetics and Molecular Biology

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases